GlassScriptPhysician profile
James H Bower
NPI 1457356503
$678.70
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $125 · 2021: $22.82.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $170.47 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $68.62 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.96 | 2019-2020 | |
| Daiichi Sankyo INC. | $49.13 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $48.70 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $44.81 | 2019 | |
| Allergan, INC. | $29.99 | 2019 | |
| Amarin Pharma, INC. | $28.04 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $27.85 | 2019 | |
| Lilly USA, LLC | $25.38 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.59 | 2019 | |
| Abbvie INC. | $22.82 | 2021 | |
| Pfizer INC. | $22.26 | 2019-2020 | |
| Edwards Lifesciences Corporation | $20.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.20 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $11.09 | 2020 | |
| Amgen INC. | $10.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.